Verastem, Inc. Payments to Acquire Available-for-sale Securities
Verastem, Inc. (VSTM) reported Payments to Acquire Available-for-sale Securities of $7.96 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-03-13
- Verastem, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $1.50M, a 93.16% decline year-over-year.
- Verastem, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Verastem, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- Verastem, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-03-31 was $6.46M, a 82.22% decline year-over-year.
- Verastem, Inc. payments to acquire available-for-sale securities for fiscal 2017 was $7.96M, a 90.31% decline from fiscal 2016.
- Verastem, Inc. payments to acquire available-for-sale securities for fiscal 2016 was $82.10M, a 58.92% decline from fiscal 2015.
- Verastem, Inc. payments to acquire available-for-sale securities for fiscal 2015 was $199.85M, a 407.74% increase from fiscal 2014.
- Verastem, Inc. payments to acquire available-for-sale securities for fiscal 2014 was $39.36M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $1.50M derived: sum of 2 quarters · filed 2018-03-13 | $1.50M derived: sum of 3 quarters · filed 2018-03-13 | $7.96M 10-K · filed 2018-03-13 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $6.46M 10-Q · filed 2017-11-07 | $28.34M derived: sum of 4 quarters · filed 2018-03-13 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $6.46M 10-Q · filed 2017-08-08 | $28.34M derived: sum of 3 quarters · filed 2018-03-13 | $48.16M derived: sum of 4 quarters · filed 2018-03-13 |
| 2017-03-31 | $6.46M 10-Q · filed 2017-05-10 | $28.34M derived: sum of 2 quarters · filed 2018-03-13 | $48.16M derived: sum of 3 quarters · filed 2018-03-13 | $52.22M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-12-31 | $21.88M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $41.70M derived: sum of 2 quarters · filed 2018-03-13 | $45.76M derived: sum of 3 quarters · filed 2018-03-13 | $82.10M 10-K · filed 2018-03-13 |
| 2016-09-30 | $19.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $23.88M derived: sum of 2 quarters · filed 2017-11-07 | $60.22M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $4.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $40.40M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $36.35M 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $199.85M 10-K · filed 2018-03-13 | |||
| 2014-12-31 | $39.36M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |